Table 1.
Baseline demographic and laboratory data.
| PBC(N=226) | PBC/SS(N=56) | P value | |
|---|---|---|---|
| Age (years) | 52.5(43.0,62.0) | 51.5(45.0,58.8) | 0.778 |
| Sex, n (%) | 0.123 | ||
| Female | 189(83.6) | 52(92.9) | |
| Male | 37(16.4) | 4(7.1) | |
| PLT (× 109/L) | 127.0(84.0,192.8) | 112.0(70.5,171.8) | 0.244 |
| INR | 1.03(0.97,1.11) | 1.01(0.97,1.08) | 0.334 |
| Alb (g/L) | 41.4(35.1,44.9) | 40.2(36.5,43.6) | 0.369 |
| Cr (μmol/L) | 60.0(52.8,71.0) | 62.1(53.5,68.0) | 0.635 |
| TB (μmol/L) | 19.3(13.4,29.9) | 16.1(12.8,25.3) | 0.182 |
| ALT (IU/L) | 56.5(34.8,82.0) | 62.0(40.0,88.5) | 0.206 |
| AST (IU/L) | 75.0(48.0,110.0) | 65.5(44.0,97.0) | 0.184 |
| ALP (IU/L) | 280.5(159.8,431.3) | 274.0(143.0,405.6) | 0.233 |
| GGT (IU/L) | 257.5(127.8,459.0) | 237.0(95.8,421.5) | 0.340 |
| Anti-AMA (%) | 162(71.7) | 39(69.2) | 0.619 |
| ANA (%) | 210(92.9) | 56(100.0) | 0.041 |
| IgG (g/L) | 16.3(14.2,19.4) | 19.3(15.5,22.2) | 0.001 |
| IgM (g/L) | 3.6(2.3,5.9) | 3.7(2.3,5.0) | 0.788 |
| Fib-4 | 3.6(1.9,7.1) | 4.2(2.4,8.6) | 0.134 |
| APRI, splenomegaly |
1.3(0.7,2.2), 71(31.4%) |
1.7(0.8.2.9), 19(33.9%) |
0.064, 0.718 |
| Duration of follow-up (months) | 21.0(14.0,38.3) | 28.0(11.0,65.0) | 0.256 |
Data are expressed as the median (interquartile range); PLT, platelet; INR, international normalized ratio; Alb, albumin; Cr, creatinine; TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; anti-AMA, antimitochondrial antibody; ANA, antinuclear antibody; Fib-4, fibrosis score; APRI, aspartate aminotransferase/platelet ratio index; IgG, immunoglobulin G; IgM, immunoglobulin M; SS, Sjögren's syndrome; and PBC, primary biliary cholangitis.